Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biomarker sub-study in platinum-resistant ovarian adenocarcinoma treated with GSK2110183 plus chemotherapy
ACTRN12613000048785Phase 2Recruiting
- Sponsor
- The Royal Women's Hospital
- Start
- Nov 2012
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of afuresertib in Malignant Ovarian Tumor and ovarian cancer, sponsored by The Royal Women's Hospital. Primary endpoint: Correlation of AKT pathway pharmacodynamic inhibition with therapeutic outcome. Started Nov 2012; status: recruiting.
02
Drugs
afuresertib
03
Conditions
Malignant Ovarian Tumorovarian cancer
Beyond the preview
Go deeper on ACTRN12613000048785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12613000048785.